Does Skin Cancer Raise White Blood Cell Count?

Skin cancer can raise your white blood cell count, but whether it actually does depends heavily on the type of cancer, how advanced it is, and what’s happening biologically inside the tumor. Most early-stage skin cancers produce no detectable change in a standard blood panel. In certain aggressive or advanced cases, though, the tumor itself can flood the body with signals that push white blood cell production into overdrive, sometimes to alarming levels. The relationship between skin cancer and white blood cells turns out to be far more layered than a simple yes or no, and it cuts in both directions.

How Some Skin Cancers Push White Blood Cells to Extreme Levels

The most dramatic white blood cell elevations linked to skin cancer come from tumors that manufacture their own growth signals. Some squamous cell carcinomas and melanomas produce a protein called granulocyte colony-stimulating factor, or G-CSF, which is the same substance your bone marrow normally uses to ramp up white blood cell production during an infection. When a tumor churns out G-CSF on its own, it essentially tricks the body into producing enormous numbers of neutrophils (the most common type of white blood cell) for no useful purpose.

How high can the count go? In one reported melanoma case, the patient’s white blood cell count exceeded 200,000 cells per microliter, with G-CSF levels rising to 780 pg/mL. For context, a normal white blood cell count sits somewhere around 4,000 to 11,000. That is roughly twenty times the upper limit of normal.¹ A case of cutaneous squamous cell carcinoma showed a similarly extreme pattern, with white blood cells reaching 111,000 per microliter alongside markedly elevated G-CSF.² These G-CSF-producing skin cancers are rare, but they tend to be aggressive, and the extreme white cell counts are themselves a warning sign of poor prognosis.

A related phenomenon is paraneoplastic hypercalcemia-leukocytosis syndrome, where the tumor produces both G-CSF and a second protein that raises calcium levels. One case report described a squamous cell carcinoma patient who presented with fever, anemia, and extremely elevated white blood cells alongside high calcium, all driven by tumor-secreted factors. The white cell count and other abnormalities resolved dramatically once chemotherapy began.³ A similar presentation has been documented even in children with skin cancer arising from the genetic condition xeroderma pigmentosum.⁴

When the Count Goes the Other Direction

Here is where the picture gets counterintuitive. Not all skin cancers raise white blood cells. In fact, some evidence suggests the opposite can happen, particularly with common, less aggressive types. A study comparing patients with basal cell carcinoma and squamous cell carcinoma to healthy controls found that white blood cell, neutrophil, and monocyte counts were actually lowest in the basal cell carcinoma group and were significantly lower in both cancer groups compared to controls.⁵

Melanoma tells a similarly complicated story. Research on untreated stage IV melanoma patients found that they had a significantly lower frequency of circulating monocytes compared to healthy volunteers, with a specific decline in one monocyte subtype called classical monocytes. Granulocyte and lymphocyte populations, on the other hand, looked roughly normal.⁶ Mouse studies have added a mechanistic piece to this puzzle, showing that melanoma can disrupt the bone marrow’s normal blood cell production through signaling molecules that shift the balance of which cell types get made.⁷

So a simple blood draw showing a normal or even low white blood cell count doesn’t rule out skin cancer. The total number on the lab report hides a lot of complexity in the proportions of different cell types underneath it.

Why Doctors Care More About the Ratio Than the Total

If you have melanoma, your oncologist is probably paying more attention to something called the neutrophil-to-lymphocyte ratio, or NLR, than to your overall white blood cell count. The NLR is just what it sounds like: the number of neutrophils divided by the number of lymphocytes in your blood. Both are types of white blood cells, but they play very different roles. Neutrophils handle acute inflammation, while lymphocytes are the backbone of the adaptive immune response that recognizes and attacks tumor cells.

A high NLR, meaning lots of neutrophils relative to lymphocytes, generally signals that the immune system is in an inflammatory state that favors tumor growth rather than tumor destruction. A meta-analysis pooling data from studies on metastatic melanoma patients treated with checkpoint immunotherapy found that patients with higher baseline NLR had roughly double the risk of death compared to those with lower NLR.⁸ Elevated NLR has also been linked to worse outcomes in patients undergoing surgical removal of metastases and in those receiving older immunotherapy regimens.⁹

One study of melanoma patients treated with the immunotherapy drug nivolumab found that an NLR of 5 or higher at baseline was a significant independent predictor of shorter survival, even after accounting for other known risk factors like elevated lactate dehydrogenase.¹⁰ The NLR essentially reflects the tug-of-war between the tumor’s inflammatory environment and your body’s ability to mount an immune attack. It is cheap, easy to calculate from a standard blood draw, and increasingly seen as a useful tool for gauging how someone might respond to treatment.

How Immunotherapy Changes the Blood Picture

If you’re undergoing immunotherapy for melanoma, your white blood cell count becomes a moving target. Checkpoint inhibitors like nivolumab and ipilimumab work by releasing the brakes on the immune system, and that has measurable ripple effects on blood cell populations.

Research tracking melanoma patients through immunotherapy cycles found that rising white blood cell counts and falling lymphocyte percentages during treatment were associated with serious immune-related side effects, particularly in the lungs and gastrointestinal tract. Patients who experienced a large increase in total white cells alongside a substantial drop in the relative proportion of lymphocytes were several times more likely to develop severe immune-related complications.¹¹

Changes in blood counts during treatment also help predict whether the therapy is working. A study of melanoma patients on checkpoint inhibitors found that increases in white blood cells and neutrophils after one month of treatment correlated with worse progression-free survival. Rising lymphocyte counts, by contrast, were a positive sign. The shift in the NLR over that first month was independently linked to treatment outcomes, suggesting that watching how the ratio changes over time is more informative than a single snapshot.¹²

Targeted therapies add another wrinkle. BRAF inhibitors, a class of drugs used for melanomas with a specific genetic mutation, can directly affect white blood cell production. One case report documented a patient who developed severe leukopenia (dangerously low white blood cells) on vemurafenib but recovered after switching to a different BRAF inhibitor, dabrafenib, despite both drugs targeting the same molecular pathway.¹³ The drugs themselves, not just the cancer, can reshape your blood count in unexpected ways.

The Eosinophil Signal

One of the more intriguing findings in melanoma research involves eosinophils, a white blood cell type most people associate with allergies and parasitic infections. Eosinophils make up only a tiny fraction of circulating white blood cells under normal conditions, but their behavior during melanoma treatment has turned out to be surprisingly meaningful.

Observational studies have found that higher eosinophil counts are associated with longer survival in advanced melanoma.¹⁴ More specifically, research on patients receiving checkpoint inhibitors showed that clinical responses to treatment were linked to eosinophil accumulation in the blood, and that immunotherapy altered the genetic and activation profile of those eosinophils.¹⁵ In other words, if your eosinophil count climbs during immunotherapy, it may be a good sign rather than a bad one. This is a relatively young area of research, but it highlights how different white blood cell subtypes can move in opposite directions and carry opposite meanings for the same patient.

The broader lesson is that a total white blood cell count is a blunt instrument. When oncologists look at blood work in melanoma patients, they want to know which cells are going up and which are going down. The tumor’s immune microenvironment matters too: a melanoma with a low ratio of lymphocytes to monocytes inside the tumor itself has been identified as a more aggressive phenotype with worse survival outcomes.¹⁶

When the “Skin Cancer” Is Already in the Blood

There is one category of skin cancer where elevated white blood cell counts are essentially the disease itself. Sézary syndrome is an aggressive form of cutaneous T-cell lymphoma, a cancer that originates in the skin’s immune cells and spills into the bloodstream. Patients with Sézary syndrome develop abnormal T lymphocytes, called Sézary cells, that circulate in the blood, infiltrate the skin, and spread to lymph nodes.¹⁷ The clinical picture includes widespread reddening of the skin, intense itching, swollen lymph nodes, and these distinctive malignant cells circulating freely in the blood.¹⁸

Sézary syndrome is fundamentally different from melanoma or squamous cell carcinoma. It is a blood cancer that happens to declare itself in the skin, rather than a skin cancer that secondarily affects the blood. But because it often begins as a chronic skin condition resembling severe eczema or dermatitis, it can initially be mistaken for a nonmalignant problem. Elevated lymphocyte counts with unusual-looking cells on a blood smear are a diagnostic hallmark, and they can be one of the earliest laboratory clues.

Can a Blood Test Catch Skin Cancer Recurrence?

Given all the ways skin cancer can alter white blood cell counts and ratios, you might wonder whether routine blood work is useful for monitoring patients after treatment. The evidence here is surprisingly sobering. A study examining follow-up strategies after melanoma surgery found that routine blood analyses were never the sole indicator of recurrent disease. The data indicated that standard blood tests and chest X-rays had limited value for catching recurrences in patients who had been treated for intermediate- and high-risk melanomas.¹⁹

This makes sense when you consider the earlier finding that many skin cancers don’t reliably move the total white blood cell count in a consistent direction. A white blood cell count that is within the normal range does not mean you are cancer-free, and one that is mildly elevated could easily be caused by a cold, stress, or a minor injury. The NLR and other ratio-based markers are more informative, but they are used for prognosis and treatment monitoring in patients already diagnosed with melanoma, not for screening or early detection.

Self-examination and dermatological follow-up remain the primary tools for catching skin cancer early. Blood work plays a supporting role once cancer has been diagnosed, especially for advanced disease, but it is not a replacement for actually looking at the skin.

Melanoma and the Bone Marrow

In rare and advanced cases, melanoma can metastasize directly to the bone marrow, the tissue that produces your blood cells. When this happens, the impact on white blood cell counts becomes unpredictable. The cancer cells physically crowd the marrow space, disrupting normal production of all blood cell lines. Patients may develop anemia, low platelet counts, abnormal white cell counts, or some combination. One documented case involved a 22-year-old man whose first sign of melanoma was discovered through a bone marrow evaluation, with no primary skin lesion ever identified.²⁰

Bone marrow involvement from melanoma is uncommon, but it illustrates the wide spectrum of ways skin cancer can interact with the blood-forming system. At one extreme, a G-CSF-secreting tumor drives white cells into the hundreds of thousands. At the other, marrow infiltration can suppress blood cell production entirely. The clinical picture depends on the biology of the individual tumor and how far the disease has spread, which is why no single blood test pattern reliably signals “skin cancer.”